Heermann K H, Wagenseil D, Lottmann S, Gerlich W H, Thomssen R
Department of Medical Microbiology, University of Göttingen, Germany.
Intervirology. 1995;38(6):316-24. doi: 10.1159/000150458.
Cellular immune responses to the HBc or HBe antigen of hepatitis B viruses contribute to the pathogenesis of hepatitis B and to the elimination of the virus. Insufficient cytotoxic immune reactions against the core antigen may be one major reason for viral persistence in the absence of severe clinical symptoms. We attempted to stop viral persistence in the animal model of congenitally infected ducks by injection of recombinant DHBc particles, together with the strong immunostimulator Freund's adjuvant. However, the duck HBc antigen (DHBcAg)-treated ducks did not develop detectable liver disease, nor was the virus persistence affected. The congenitally infected ducks did not contain antibodies against DHBcAg before injection despite continuous production of duck hepatitis B virus, and developed only a weak transient antibody response after injection of recombinant DHBcAg together with Freund's adjuvant. Noninfected ducks developed, in contrast, a strong antibody response to the injected DHBcAg. We conclude that congenitally infected ducks are immunotolerant to DHBcAg and cannot be cured by immunotherapy with exogenous recombinant DHBcAg.
针对乙肝病毒核心抗原(HBc)或e抗原(HBe)的细胞免疫反应,在乙肝发病机制及病毒清除过程中发挥作用。在缺乏严重临床症状的情况下,针对核心抗原的细胞毒性免疫反应不足可能是病毒持续存在的一个主要原因。我们试图通过注射重组鸭乙肝核心颗粒(DHBc)并联合强免疫刺激剂弗氏佐剂,来终止先天性感染鸭动物模型中的病毒持续感染。然而,接受鸭乙肝核心抗原(DHBcAg)治疗的鸭并未出现可检测到的肝脏疾病,病毒持续感染情况也未受影响。尽管先天性感染鸭持续产生鸭乙肝病毒,但在注射前并不含有针对DHBcAg的抗体,在注射重组DHBcAg联合弗氏佐剂后,仅产生了微弱的短暂抗体反应。相比之下,未感染鸭对注射的DHBcAg产生了强烈的抗体反应。我们得出结论,先天性感染鸭对DHBcAg具有免疫耐受性,无法通过外源性重组DHBcAg免疫疗法治愈。